AbbVie (ABBV) Wins Health Canada Approval for Boey

AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In.

On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum neurotoxin serotype E with a rapid onset and short duration for temporarily improving glabellar lines.

Also on June 23, Canaccord raised its price target on AbbVie to $273 from $265 and maintained a Buy rating. Canaccord updated its model following AbbVie’s announced acquisition of Apogee Therapeutics (APGE), which Canaccord believes makes strong strategic sense by adding a potential mega-blockbuster immunology asset for AD and asthma that could become a major growth driver over the next decade.

AbbVie (ABBV) Wins Health Canada Approval for Boey

AbbVie also announced that the European Commission approved Maviret, an oral pangenotypic direct-acting antiviral therapy, for treating acute hepatitis C virus infection in adults and children aged 3 years and older. Maviret is now the only treatment approved in the European Union for both acute and chronic HCV infection.

AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1